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Activation of coagulation and fibrinolysis is frequently encountered among cancer patients.
Such tumors are supposed to be associated with higher risk of invasion, metastases and even-
tually worse outcome. The aim of this study is to explore the prognostic value of blood coag-
ulation tests for lung cancer patients. The study comprised 110 lung cancer patients.
Pretreatment blood coagulation tests including PT, aPTT, PTA, INR, D-dimer, fibrinogen levels
and platelet counts were evaluated. The plasma level of all coagulation tests revealed statis-
tically significant difference between patient and control group (p < 0.001). There was a signif-
icant association between D-Dimer levels and histological subtypes of NSCLC, pointing an
elevated plasma D-dimer level in squamous cell cancer (p Z 0.035). Patients with extensive
stage SCLC exhibited evidently higher levels of D-Dimer, INR and PLT (p Z 0.037,
p Z 0.042, p Z 0.04, respectively). Prolongation of PT and INR had statistically significant
adverse effect on survival (p Z 0.05 and p Z 0.014, respectively). Although prolonged aPTT
and high levels of D-dimer was associated with worse survival, the difference was not statisti-
cally significant (pZ 0.117, pZ 0.104). Multivariate analysis revealed INR as the sole indepen-
dent prognostic variable among coagulation parameters (pZ 0.05). In conclusion, elevation of
PT and INR are associated with decreased survival in lung cancer patients.
ª 2012 Elsevier Ltd. All rights reserved.versitesi, Onkoloji Enstitusu,
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2.11.007Introduction
The relationship between cancer and coagulation is char-
acterized by several mechanisms pointing that tumor
biology and coagulation are closely linked processes.1 It is
now well established that clotting activation is frequently
encountered in cancer, typically manifesting as a low-grade.
452 F. Tas et al.disseminated intravascular coagulation or venous throm-
boembolism either due to cancer itself or agents used for
treatment. Patients with tumors of lung, pancreas and
gastrointestinal tract are supposed to be more prone to
hypercoagulable state.2 Thus, clinical consequences of
thrombosis can be serious with a negative impact on the
course of disease, increasing morbidity and mortality.
Importantly, rather than being merely a trigger of
increased thromboembolic events, cancer induced hemo-
static activity has been shown to promote tumor growth
and cancer cell dissemination.3 Recent studies have sug-
gested that hemostatic abnormalities observed in cancer
patients may lead to recruitment of inflammatory cells,
generation of tumor stroma and angiogenesis.4 For
instance, tumors activating coagulation system are
supposed to behave more aggressively with higher risk of
invasion and metastasis. High levels of circulating
biomarkers resembling activated coagulation and fibrino-
lytic system such as fibrinogen, fibrin (ogen) split products
and D-dimer have been associated with decreased survival
for several tumor types in previous studies.5e8 Research
activities among lung cancer patients investigating the
relationship between activated hemostatic system and
prognosis have revealed similar results.9e12 These findings
have emerged studies evaluating the effect of anticoagu-
lants in adjunct with chemotherapy mainly in SCLC
patients.13 Although a survival benefit was observed in that
study, sufficient evidence of such an advantage was not
provided for cancer patients in general. However, under-
standing the potential pathways responsible for activated
hemostatic/fibrinolytic activity may help indentifying
surrogate markers for novel therapeutic targets in the near
future.
The aims of the current study are to confirm whether
some coagulation abnormalities are more frequently
encountered with lung cancer and to delineate the corre-
lation of these coagulation tests with other clinical and
laboratory variables.Patients and methods
This study comprised 110 consecutive patients with histo-
logically or cytologically confirmed non-small-cell lung
cancer (NSCLC) and small-cell lung cancer (SCLC) treated in
outpatient or inpatient clinics of Istanbul University, Insti-
tute of Oncology. Patients with bidimensionally measurable
disease without history of chemo/radiotherapy in the last
six months were included in the study. The pathological
diagnosis of lung cancer was established in accordance with
the revised World Health Organization classification of lung
tumors14 and staged relying on the revised TNM staging for
lung cancer.15 The pretreatment evaluation included
detailed clinical history and physical examination with
a series of biochemistry tests, complete blood cell counts
and coagulation tests. Those with ECOG performance status
2 and appropriate blood chemistry tests received
chemotherapy on outpatient basis comprising platinum
compounds with/without radiotherapy depending on the
stage of disease. Follow up programs consisted of clinical,
laboratory, radiological assessments performed at 8 weeks
intervals during chemotherapy or every 12 weeks for noanticancer treatment. Response to treatment was deter-
minated according to revised RECIST criteria version 1.1.16
For comparison of coagulation assays, age and sex
matched 50 healthy controls were included in the analysis.
Institutional review board approval and informed consent
was obtained from all patients prior to the commencement
of the study.
Biochemical assays
Venous blood samples were collected in tubes containing
sodium citrate before initiation of chemotherapy for the
measurement of parameters, centrifuged immediately and
studied within 2 h. D-dimer values were determined by
Microparticle Enzyme Immunoassay (MEIA) using AxSYM
analyzer (Abbott Laboratories, Chicago, Illinois, USA)
following the manufacturer’s instructions. Commercially
available reagents provided by the kinetic nephelometric
detection system using Diagon Dia-Timer 4 (Diagon Ltd,
Budapest, Hungary) were employed for PT, aPTT and
Fibrinogen measurement. Prothrombin activity (PTA)
reflects calibration of PT. For calibration, sample pool is
supposed to have 100% activity. After serial dilutions 50%,
25% and 12.5% activity of sample is obtained, tested again
in the device and each value corresponding to a level of
activity is plotted in the graphics of PT calibration. The
device utilizes these values for generating a logelog axis.
Each result positioned to this axis corresponds to an activity
of prothrombin measured as percentage.
Statistical analysis
Continuous variables were categorized using median values
as cut-off point. Assessment of relationships, comparisons
between various clinical/laboratory parameters and coag-
ulation tests including D-dimer, fibrinogen, PT and aPTT
were accomplished using ManneWhitney U test and Krus-
kaleWallis test for two and three groups, respectively. For
comparison of D-dimer values among different histologic
subtypes Kruskal Wallis test was performed initially and
then Bonferroni correction was applied. Survival was
calculated from the date of first contact of patient to death
resulting from any cause or to last contact with the patient
or any family member. KaplaneMeier method was used for
estimation of survival distribution; differences in survival
were assessed by the log-rank statistic. Multivariate
survival analysis was performed using the Cox’s propor-
tional hazards regression model. A p value <0.05 was
considered significant in this purely exploratory analysis.
Statistical analysis was carried out using SPSS 16.0
software.
Results
From June 2010 to July 2011, 110 consecutive patients with
a pathologically confirmed diagnosis of lung cancer were
enrolled into this study. Baseline histopathological charac-
teristics and demographic features of patients are listed in
Table 1. Median age at diagnosis was 59-years old, range
35e80 years, where males constituted majority of the
group (n Z 100, 91%).
Table 1 Patient characteristics.
%
No. of patients: 110 100
Age, years
Median (range): 59 (35e80)
60 52
60þ 48
Gender
Male 91
Female 9
Histology
Non-small cell 84
Adeno 30
Squamous 26
Others (unclassified) 28
Small cell 16
Stage of disease
Non-small cell lung cancer
Local (stage I þ II) 6
Locally advanced (stage III) 33
Metastatic (stage IV) 45
Small cell lung cancer
Limited 5
Extensive 11
Serum hemoglobin level
Low (<12 g/dL) 29
Normal (>12 g/dL) 71
Serum WBC count
Normal (<11,000) 77
Elevated (>11,000) 23
Serum platelet count
Normal (<350,000) 65
Elevated (>350,000) 35
Erythrocyte sedimentation rate (/h)
Normal (<40) 45
Elevated (>40) 55
Serum LDH level
Normal (<450 U/L) 75
Elevated (>450 U/L) 25
Response to chemotherapy
Responsive (CR* þ PR*) 47
Non-responsive (SD* þ PD*) 53
Last status
Alive 72
Dead 28
*CR Z complete response, PR Z partial response, SD Z stable
disease, PD Z progressive disease.
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and healthy controls
The plasma level of all coagulation tests including D-
dimer, fibrinogen (F), prothrombin time (PT), activated
partial thromboplastin time (aPTT), international
normalized ratio (INR) and platelet counts revealed
statistically significant difference between patient and
control group (p < 0.001 for all variables but for PT;
p Z 0.045) (Table 2).Coagulation tests and their correlations with other
variables
The relationships between clotting tests and other laboratory
variables including lactate dehydrogenase (LDH), erythro-
cyte sedimentation rate (ESR), hemoglobin (Hb) level, white
blood cell (WBC) count and clinical characteristics of the
patients are summarized in Table 3. There was a statistically
significant association between D-Dimer levels and histolog-
ical subtypes of NSCLC, squamous cell lung cancer patients
exhibited higher plasma D-dimer levels when compared with
nonsquamous carcinoma patients excluding adenocarcinoma
subtype (p Z 0.007). Extensive stage SCLC was also associ-
ated with evidently higher levels of D-Dimer, INR and PLT
when compared with limited stage disease (for D-dimer; 200
vs 718 IU/mlpZ 0.037, for INR; 1.02 vs 1.1pZ 0.042, for PLT;
248 000/mm3 vs 347 000/mm3, pZ 0.04). However, a similar
association between stages of NSCLC and D-Dimer levels was
not demonstrated (pZ 0.554). Besides therewas statistically
no significant relationship betweenagedistributions,Hb,LDH
levels, WBC counts and coagulation tests. A significant
correlation was found between gender and coagulation
factor tests such as PT, aPTT and INR (pZ 0.043, pZ 0.008
and p Z 0.014, respectively) but not for fibrinogen and D-
dimer, suggesting a higher tendency to activated coagulation
cascade among male patients when compared with female
subjects. In addition, elevated platelet counts were associ-
ated with resistance to chemotherapy (252 000/mm3 vs
337 000/mm3, p Z 0.048), but other factors involved in
coagulation pathway did not seem to correlate with response
to chemotherapy. Analogously, there was not a significant
correlation with any of the coagulation tests and ESR or
platelet counts.Survival analysis
Median follow-up time was 20.3 weeks (range 4.4e72.6
weeks). Median survival for all patients was 57 weeks (95%
CI 45.6e68.3 weeks). At the end of observation, 31 patients
(28%) were dead due to disease related or unrelated
factors.
Evaluation of the effect of clinical and laboratory vari-
ables confirmed the acknowledged negative impact of
elderly age (above 60 years) and primary resistance to
chemotherapy on survival (p Z 0.009 and p < 0.001,
respectively) (Table 4). Among the laboratory variables,
elevated serum LDH level was associated with worse overall
survival (62.1 vs 30.8 weeks for normal and elevated LDH
levels, respectively, p Z 0.001). Evaluation of clotting
factors revealed that prolongation of PT and INR had
statistically significant adverse effect on survival (pZ 0.05
and p Z 0.014, respectively) (Figs. 1 and 2). Although
patients with higher levels of D-Dimer, fibrinogen and aPTT
had prominently worse outcome when compared with those
below the median range, the difference in survival was not
statistically significant (6-months survival rates 80.3 vs
68.5%, pZ 0.117; 81.6 vs 75.1%, pZ 0.186; 79.3% vs 64.9%,
p Z 0.104, respectively). Multivariate analyses were per-
formed with Cox’s proportional hazards regression anal-
yses. Prognostically significant variables with a p value
0.05 including age, INR, LDH and response to
Table 2 The values of serum coagulation tests in patients with lung cancer and healthy controls.
Coagulation tests Patients (n Z 110) Controls (n Z 50) p
Median Range Median Range
D-dimer (IU/ml) 360 22e5900 37.8 0e118.5 <0.001
Fibrinogen (mg/dl) 410 131e1705 245 166e463 <0.001
PT (sec) 14.6 9.4e18.8 14.2 10.5e16.8 0.045
aPTT (sec) 27.2 19.8e44.0 31.8 24.6e48.0 <0.001
PTA (%) 81 51.1e276 88.4 69.8e139.9 <0.001
INR 1.10 0.68e2.70 1.01 0.76e1.29 <0.001
Platelet (103/mm3) 289 81e710 201 163e254 <0.001
454 F. Tas et al.chemotherapy were included in the analysis; PT was
excluded due to the high correlation with INR. Conse-
quently, only elevated INR was independently associated
with worse survival in addition to elderly age (for age, HR:
0.10, 95% CI 0.013e0.813, pZ 0.031; for INR, HR: 0.23, 95%
CI: 0.05e1.045, pZ 0.05). 1 year survival rate for patients
with high and low INR was 44.8% (1.1) and 74.1% (1.1)
respectively.Table 3 Results (median and range) of comparisons between t
Parameters Coagulation testsa
D-dimer (IU/ml) Fibrinogen
(mg/dl)
PT (sec)
Gender
Male 363 420 14.7
Female 227
(p Z 0.567)
369
(p Z 0.724)
14.1
(p Z 0.043)
Histology
Non-small cell
Adeno 281 415 14.4
Squamous 733 363 14.6
Others 227
(p Z 0.035)**
429
(p Z 0.557)
14.9
(p Z 0.982)
Stage of disease
Small cell lung
cancer
Limited 200 378 14.3
Extensive 718
(p Z 0.037)
425
(p Z 0.648)
14.6
(p Z 0.315)
Serum Platelet
count
Normal 313 337 14.5
Elevated 388
(p Z 0.065)
521
(p Z 0.001)
14.8
(p Z 0.05)
ESR
Normal 226 329 14.1
Elevated 521
(p Z 0.093)
521
(p < 0.001 )
15.3
(p < 0.001)
Response to
chemotherapy
Responsive 222 377 14.6
Non-responsive 511
(p Z 0.068)
438
(p Z 0.396)
14.4
(p Z 0.806)
Bold italics means the values that statistically significant (p < 0.05).
**For adeno vs squamous, p Z 0.118; squamous vs others, p Z 0.007
a Median values for each parameter.Discussion
A systematic activation of clotting system has been
observed in cancer patients which is usually reflected by
subclinical abnormalities of conventional coagulation
tests.17,18 Despite numerous studies dealing with the causes
of hypercoagulability and thromboembolic complications inhe coagulation tests and various clinical parameters.
aPTT (sec) PTA (%) INR PLT (103/mm3)
27.7 78.2 1.12 289
23.7
(p Z 0.008)
87.1
(p Z 0.034)
1.04
(p Z 0.014)
324
(p Z 0.524)
26.9 81 1.1 287
27.2 79.5 1.09 292
28.3
(p Z 0.641)
75.5
(p Z 0.944)
1.15
(p Z 0.68)
285
(p Z 0.457)
26.5 87.4 1.02 248
26.3
(p Z 0.914)
81.0
(p Z 0.073)
1.1
(p Z 0.042)
347
(p Z 0.040)
27.6 83 1.09
26.7
(p Z 0.548)
76.3
(p Z 0.024)
1.13
(p Z 0.018)
e
27.0 83.8 1.04 265
27.4
(p Z 0.401)
74.5
(p < 0.001)
1.14
(p Z 0.002)
357
(p Z 0.002)
26.7 81 1.09 252
27.7
(p Z 0.154)
81
(p Z 0.947)
1.09
(p Z 0.636)
337
(p Z 0.048)
; adeno vs others p Z 0.455.
Table 4 (continued )
Characteristic
Overall survival
Median
(weeks)
6-Month
(SD) (%) p Value
Elevated (>median value) 50.5 75.1 (8.3)
PT
Normal (<median value) NR 80.7 (6.6) 0.05
Elevated (>median value) 30.8 58.8 (10.6)
aPTT
Normal (<median value) NR 79.3 (7.1) 0.104
Elevated (>median value) 30.8 64.9 (9.9)
Coagulation assays in lung cancer 455patients suffering from malignancy, the mechanisms are
still not completely understood. There is some evidence
that the activation of coagulation and fibrinolytic system by
neoplastic cells facilitates invasiveness and metastases.12
Thus, the extent of such activation has been associated
with tumor stage and prognosis in some malignancies such
as breast, colorectal and lung cancer.7,19,20 The purpose of
this study was to gain further evidence for prognostic value
of routine clotting tests while predicting lung cancer
patients’ outcome.
So far various markers reflecting activated hemostatic
system such as thrombocytosis, hyperfibrinogenemia andTable 4 Univariate analyses.
Characteristic Overall survival
Median
(weeks)
6-Month
(SD) (%)
p Value
Age (years)
<60 57 86.3 (5.3) 0.009
>60 37 62.9 (7.6)
Gender
Male 57 71.8 (5.3) 0.415
Female 49 75.0(2.1)
Histology
Non-small cell 57 77.1 (5.0) 0.446
Small cell 50.5 75.0 (2.1)
Non-small cell subtypes
Adeno 62.1 86.4 (6.4) 0.358
Squamous 37.8 78.3 (8.7)
Others (unclassified) NR# 65.7 (10.1)
Stage of disease
Non-small cell
Nonmetastatic 62 88.9 (5.3) 0.109
Metastatic 57 65.1 (8.1)
Small cell lung cancer
Limited NR 100 0.103
Extensive 24.4 48.9 (16.6)
Serum hemoglobin level
Low NR 68.0 (8.9) 0.412
Normal 57.0 76.9 (5.7)
Serum WBC count
Normal 57.0 72.8 (5.6) 0.829
Elevated NR 79.8 (9.2)
Erythrocyte sedimentation
rate
Normal 62 85.7 (6.8) 0.524
Elevated NR 73.0 (7.8)
Serum LDH level
Normal 62.1 86.0 (4.4) 0.001
Elevated 30.8 50.1 (13.6)
Response to chemotherapy
Responsive (PR* and CR*) 27.0 94.5 (3.8) <0.001
Non-responsive
(SD* and PD*)
NR 54.6 (9.6)
D-dimer
Normal (<median value) 62.1 80.3 (6.4) 0.117
Elevated (>median value) 50.5 68.5 (9.5)
Fibrinogen
Normal (<median value) NR 81.6 (6.8) 0.186
INR
Normal (<median value) NR 81.7 (6.4) 0.014
Elevated (>median value) 30.8 57.5 (9.6)
Platelet
Normal (<median value) 62.1 69.9 (7.3) 0.763
Elevated (>median value) 57.0 78.5 (6.4)
Bold values represent statistically significant values (p < 0.05).
#NR Z not reached. *CR Z complete response, PR Z partial
response, SD Z stable disease, PD Z progressive disease.elevated D-dimer levels have been demonstrated in
different types of cancer involving head and neck, colon,
prostate and lung cancer.21,22 The current study also
confirmed the existence of a significant difference between
healthy control subjects and lung cancer patients with
respect to coagulation tests such as PT, aPTT, INR, D-dimer,
fibrinogen levels and platelet counts. In our study D-dimer
values were remarkably elevated in patient group when
compared with healthy subjects due to activation of both
coagulation and fibrinolytic system (p < 0.001). Although
the mechanism by which coagulation is activated in cancer
is multifactorial, tissue factor (TF) is traditionally recog-
nized to play an important role in this process. Increased
level of expression of tissue factor by cancer cells and
release of TF by platelets, monocytes and stromal cellsFigure 1 Overall survival curves in patients with lung cancer
according to PT levels (p Z 0.05). <Median value, solid lines;
>median value, dashed lines.
Figure 2 Overall survival curves in patients with lung cancer
according to INR levels (pZ 0.014). <Median value, solid lines;
>median value, dashed lines.
456 F. Tas et al.contribute as a major source of procoagulant
activity.17,23,24 The coagulation cascade initiated by this
transmembrane glycoprotein triggers a number of events
which in turn converts prothrombin to thrombin and
generates the insoluble fibrin clot. Assuming that fibrinogen
level is normal, a prolonged PT signifies a deficiency,
depletion of coagulation factors or presence of a specific
inhibitor of factors involved in this cascade.25 Prolongation
of PT was strongly associated with poor prognosis in non-
small cell lung cancer patients previously but in that report
the multivariate model did not confirm the prognostic
relevance of any coagulation factor.26 Our study had also
revealed the significance of prolonged PT and INR in
univariate analysis but additionally the multivariate anal-
ysis of survival emphasized the impact of INR for lung
cancer patients. There was also a tendency toward
decreased survival for patients with prolonged aPTT but it
was not statistically significant (6 months survival rate
79.3% vs 64.9%, p Z 0.104).
Various studies in this era have demonstrated that
increased D-dimer as a marker of coagulation and fibrino-
lytic activation is a strong predictor of poor prognosis for
non-small-cell lung cancer.27e29 In the current study there
was a tendency toward decreased survival for patients with
elevated D-dimer levels but it did not reach statistical
significance (6 months survival rate 80.3% vs 68.5%,
p Z 0.117). However, in our SCLC patient subgroup
extensive stage disease was associated with higher levels of
D-dimer.
In clinical practice, prolongation of PT with aPTT due to
depletion of coagulation tests is a well-known marker for
disseminated intravascular coagulation (DIC). In this state,
plasminogen activator inhibitor-1 (PAI-1) and tissue factor
(TF) are induced excessively and production of thrombo-
modulin is restricted to the vascular endothelium.30 Our
findings also support the presence of a low grade DIC in lung
cancer patients and its unfavorable effect on survival.Fibrinogen as one of the major plasma proteins is synthe-
sized in the liver and secreted into the circulation. Although
fibrinogen synthesis is significantly upregulated by inflam-
matory stimulation, theprecisemechanism inmalignancyhas
not been elucidated yet. Inflammatory cytokines such as IL-6
secreted from cancer cells are supposed to induce production
of fibrinogen from the liver. Thus, hypersecretion of fibrin-
ogenmay overcomedepletion of coagulation tests by ongoing
DIC process.31 In our study patients with elevated fibrinogen
levels had a tendency to decreased survival which did not
reach statistical significance. This finding is in concordance
with the recent study reporting the correlation of particularly
high fibrinogen levels with shorter disease-free survival in
colorectal cancer.32
Studies conferring evidence of anticoagulation for
cancer patients have revealed conflicting results. There is
not sufficient data for survival benefit from oral anticoag-
ulants in cancer patients generally; however heparin has
provided an advantage for improved survival encouraging
administration of novel anticoagulant therapies for both
antithrombotic and antitumor effect.33 Besides, identifi-
cation of subgroups which will benefit most from anti-
coagulation is necessary. Our study may suggest a particular
subset of patients with poor prognosis as a candidate for
anticoagulation. Although high INR is supposed to be asso-
ciated with hemorrhagic diathesis for patients under oral
anticoagulation therapy, it also reflects a depletion of
coagulation tests due to increased thrombotic process in
our patient group. However further investigation is
required before adjusting these assumptions to our daily
practices.
The current study confirms that subclinical changes in
coagulation-fibrinolytic system are often present in lung
cancer. Prolongations of PT and INR have been associated
with poor prognosis in univariate analysis and multivariate
analyses have revealed the negative impact of elevated INR
on survival. Based on these findings, we may advocate the
use of coagulation assays particularly PT and INR test in any
new lung carcinoma patient to provide a foresight about
the outcome and constitute a surrogate marker for treat-
ment with novel anticoagulants in the near future.
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